Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules

Core Viewpoint - Mangoceuticals, Inc. has entered into agreements for a registered direct offering and a concurrent private placement, expecting to raise approximately $2.5 million in gross proceeds [1][3]. Group 1: Offering Details - The transactions involve the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant at an exercise price of $1.4245 [2]. - The offering price per Common Unit is set at $1.295, while the Pre-Funded Unit is priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Information - Aegis Capital Corp. is the exclusive placement agent for the offerings, and Lucosky Brookman LLP is acting as counsel to the Company [4]. - The registered direct offering is made under an effective shelf registration statement previously filed with the SEC [4]. - The securities in the private placement are not registered under the Securities Act and are offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing health and wellness products via a secure telemedicine platform, particularly in men's health sectors such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [8]. - The telemedicine platform allows consumers to request prescriptions, which are reviewed by a physician and fulfilled through a partner compounding pharmacy [9].